Company intelligence / Profile preview

Be Biopharma

Cambridge, Massachusetts, United Statesbe.bio ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Currently conducting Phase 1/2 BeCoMe-9 Trial for BE-101 in Hemophilia B with FDA Fast Track Designation. BE-102 for Hypophosphatasia has been nominated as second development candidate.

Therapeutic areas: OtherOncologyRare DiseasesHematology
Modalities: Engineered B Cell Medicines (BCMs)
Industry: Biotech

Drug pipeline

3 assets

BE-102

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers SquibbTakeda VenturesSeattle Children's Research Institute

Beyond the preview

Go deeper on Be Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Be Biopharma.

Explore the full profile